Pfizer pipeline update Pipeline represents progress of R&D programs since 5/12/11 Included are 79 NMEs plus 24 additional indications 14 14 Projects Projects discontinued discontinued since last since last update update Pfizer Pipeline Snapshot as of August 11, 2011 Recent Approvals-Eliquis (Apixaban) for Venous Thromboembolism Prevention (EU) - Oxecta (formerly Pfizer Pipeline Snapshot Pipeline represents progress of R&D programs as of November 2, 2021 13 programs advanced or are new 16 programs discontinued since last update Included are 59 NMEs, 35 additional indications Discovery Projects Phase 1 27 Phase 2 29 Phase 3 29 Registration 9 Total 94 Snapshot as of Pfizer Pipeline November 2, 2021 Discovery Pipeline represents progress of R&D programs as of August 7, 2014 Included are 61 NMEs, 17 additional indications, plus 5 biosimilars 4 projects discontinued since last update Phase 2 Phase 3 35 23 20 6 Phase 1 Total 84 Discovery Projects 3 programs advanced or are new 0 projects discontinued since last update Pfizer Pipeline Snapshot as of identified in this list. Updated as of October 29, 2024. It With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements which target unmet medical need or represent significant Pfizer Pipeline – January 29, 2019 (cont’d) 6 Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer. With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements which target unmet medical need or represent significant Pfizer’s goal of delivering up to 25 breakthroughs to patients by the year 2025 has 38 such opportunities to draw from as of today, including the company’s 20-valent Pfizer business executives and scientific leadership will provide updates on the company’s potential near-term product launches and key high-value pipeline programs, both of In recent years, we have evaluated and improved our research and development (R&D) methods in order to deliver to patients a sustainable flow of novel medicines and vaccines. com Therapeutic Area Compound Name Mechanism of Action Indication Phase With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements which Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer. 10. With a vie w to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant Pipeline represents progress of R&D programs as of October 30, 2018 Included are 52 NMEs, 42 additional indications, plus 5 biosimilars 1 project discontinued since last update Phase 2 Phase 3 32 25 30 11 98 Phase 1 Total Discovery Projects Pfizer Pipeline 13 programs advanced or are new 3 projects discontinued since last update Pfizer Pipeline identified in this list. Oncology (2 of 2) Compound Name Mechanism of Pfizer Pipeline Snapshot Pipeline represents progress of R&D programs as of February 2, 2021 14 programs advanced or are new 3 programs discontinued since last update Included are 64 NMEs, 31 additional indications, plus 0 biosimilar Discovery Projects Phase 1 27 Phase 2 35 Phase 3 24 Registration 9 Total 95 Snapshot as of Pfizer Pipeline Pipeline represents progress of R&D programs since 2/28/11 Included are 90 NMEs plus 24 additional indications 14 14 Projects Projects discontinued discontinued since last since last update update Pfizer Pipeline Snapshot as of May 12, 2011 Phase 2Phase 2 Phase 3 Phase 3 In Reg. Ethics & Compliance Each of us is responsible ; Responsible Business Breakthroughs that change patients’ lives Pipeline represents progress of R&D programs since 9/27/10 Included are 93 NMEs plus 25 additional indications 15 15 Projects Projects discontinued discontinued since last since last update update Pfizer Pipeline Snapshot as of February 28, 2011 Recent Approval Xiapex for Dupuytren’s Contracture (E. With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or last update Phase 2 Phase 3 34 22 28 12 96 Phase 1 Total Discovery Projects 10 programs advanced or are new 8 Mylotarg (gemtuzumab ozogamicin) for 1projects discontinued since last update Pfizer Pipeline Snapshot as of July 31, 2018 Pfizer Pipeline Snapshot as of May 1, 2018 Registration Recent Approvals Pfizer Pipeline Snapshot Pipeline represents progress of R&D programs as of February 2, 2021 14 programs advanced or are new 3 programs discontinued since last update Included are 64 NMEs, 31 additional indications, plus 0 biosimilar Discovery Projects Phase 1 27 Phase 2 35 Phase 3 24 Registration 9 Total 95 Snapshot as of Pfizer Pipeline Pipeline represents progress of R&D programs since 8/11/11 Included are 72 NMEs plus 23 additional indications 12 12 Projects Projects discontinued discontinued since last since last update update Pfizer Pipeline Snapshot as of November 10, 2011 Recent Approvals-Xalkori (crizotinib) for ALK-Positive Non-Small Cell Lung Cancer (U. com. Regulatory Designations – See Definitions in Backup. As a result, NEW YORK and MAINZ, GERMANY, AUGUST 23, 2022 — Pfizer Inc. With a vie w to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant Pfizer Pipeline Snapshot Pipeline represents progress of R&D programs as of May 4, 2021 17 programs advanced or are new 2 programs discontinued since last update Included are 68 NMEs, 31 additional indications, plus 0 biosimilar Discovery Projects Phase 1 30 Phase 2 37 Phase 3 22 Registration 10 Total 99 Snapshot as of Pfizer Pipeline May 4, 2021 Pfizer Pipeline Snapshot Pipeline represents progress of R&D programs as of May 4, 2021 18 programs advanced or are new 2 programs discontinued since last update Included are 69 NMEs, 31 additional indications, plus 0 biosimilar Discovery Projects Phase 1 30 Phase 2 38 Phase 3 22 Registration 10 Total 100 Snapshot as of Pfizer Pipeline May 4, 2021 People. With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or identified in this list. With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements which. Oncology (2 of 2) Compound Name Mechanism Pfizer Pipeline Snapshot Pipeline represents progress of R&D programs as of November 2, 2021 13 programs advanced or are new 16 programs discontinued since last update Included are 59 NMEs, 35 additional indications Discovery Projects Phase 1 27 Phase 2 29 Phase 3 29 Registration 9 Total 94 Snapshot as of Pfizer Pipeline November 2, 2021 Discovery Pfizer Pipeline Snapshot Pipeline represents progress of R&D programs as of August 1, 2023 8 programs advanced or are new 9 programs discontinued since last update Included are 59 NMEs, 31 additional indications Discovery Projects %PDF-1. Take a deep dive into the investigational medicines and vaccines we’re working on. 1. 49 3535 25 25 9 Phase 1 Total 118 Discovery Projects In these materials, Pfizer disclose s Mechanism of Action (MOA) information for some candidates in Phase 1 and for all candidates from Phase 2 through regulatory approval. S. Executives Our senior-most leadership ; Board Members The people steering our company ; Scientists Our experts making discoveries ; Patient Stories Our patients ; Colleague Stories Our colleagues ; Responsibility. Explore the Product Pipeline. ) Phase 2Phase 2 Phase 3 Phase 3 In Reg. diff) vaccine effort Pfizer expects sales of Comirnaty, the Covid vaccine it developed with German company BioNTech, and its antiviral pill Paxlovid, to fall 62 per cent to $21. ) last update Phase 2 Phase 3 35 8622 23 6 Phase 1 Total Discovery Projects 9 programs advanced or are new 2 projects discontinued since last update Immunization to Prevent Invasive Meningococcal Disease (US) Pfizer Pipeline Snapshot as of February 27, 2015 Pfizer Pipeline Snapshot as of November 6, 2014 Registration Recent Approvals NEW YORK--(BUSINESS WIRE)-- As part of a two-day virtual Investor Day, Pfizer Inc. U. In these materials, Pfizer discloses Mechanism of Action (MOA) information for some candidates in Phase 1 and for all candidates from Phase 2 through regulatory approval. 5bn in 2023, compared to last year. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced updated efficacy results from a A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and in its subsequent Pfizer hosted a discussion with sell-side analysts to provide an update on one of the vaccine pipeline items – a second-generation Clostridioides difficile (C. With a vie w to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant Pipeline represents progress of R&D programs as of May 1, 2018 Included are 49 NMEs, 39 additional indications, plus 8 biosimilars 8 projects discontinued since last update Phase 2 Phase 3 30 18 29 10 87 Phase 1 Total Discovery Projects 10 programs advanced or are new 14 projects discontinued since last update Pfizer Pipeline Pfizer Pipeline Snapshot Pipeline represents progress of R&D programs as of November 2, 2021 13 programs advanced or are new 16 programs discontinued since last update Included are 59 NMEs, 35 additional indications Discovery Projects Phase 1 27 Phase 2 29 Phase 3 29 Registration 9 Total 94 Snapshot as of Pfizer Pipeline November 2, 2021 Discovery identified in this list. With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or In these materials, Pfizer disclose s Mechanism of Action (MOA) information for some candidates in Phase 1 and for all candidates from Phase 2 through regulatory approval. (NYSE: PFE) provided an extensive overview of pipeline advances and shared updates on the Company’s efforts to battle the COVID-19 pandemic on multiple fronts, including new data on the BNT162b2 vaccine candidate being developed in collaboration with BioNTech SE. 7 %µµµµ 1 0 obj >/Metadata 4922 0 R/ViewerPreferences 4923 0 R>> endobj 2 0 obj > endobj 3 0 obj > endobj 4 0 obj >/XObject >/Font >/ProcSet[/PDF/Text Pfizer Pipeline Snapshot Pipeline represents progress of R&D programs as of May 4, 2021 17 programs advanced or are new 2 programs discontinued since last update Included are 68 NMEs, 31 additional indications, plus 0 biosimilar Discovery Projects Phase 1 29 Phase 2 38 Phase 3 22 Registration 10 Total 99 Snapshot as of Pfizer Pipeline May 4, 2021 last update Phase 2 Phase 3 35 20 34 7 Phase 1 Total 96 Discovery Projects 11 programs advanced or are new 3 projects discontinued since last update Pfizer Pipeline Snapshot as of May 2, 2017 Pfizer Pipeline Snapshot as of January 31, 2017 Registration Recent Approvals -Bavencio (avelumab) for Merkel Cell Carcinoma (US) Pfizer Pipeline Snapshot Pipeline represents progress of R&D programs as of July 28, 2021 8 programs advanced or are new 5 programs discontinued since last update Included are 66 NMEs, 34 additional indications Discovery Projects Phase 1 29 Phase 2 40 Phase 3 23 Registration 8 Total 100 Snapshot as of Pfizer Pipeline July 28, 2021 Discovery In these materials, Pfizer disclose s Mechanism of Action (MOA) information for some candidates in Phase 1 and for all candidates from Phase 2 through regulatory approval. Vepdegestrant is being co-developed with Arvinas Pfizer Pipeline Snapshot Pipeline represents progress of R&D programs as of May 3, 2022 15 programs advanced or are new 4 programs discontinued since last update Included are 65 NMEs, 31 additional indications Discovery Projects Phase 1 30 Phase 2 31 Phase 3 29 Registration 6 Total 96 Snapshot as of Pfizer Pipeline May 3, 2022 Discovery Projects In these materials, Pfizer disclose s Mechanism of Action (MOA) information for some candidates in Phase 1 and for all candidates from Phase 2 through regulatory approval. With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or Pfizer Pipeline Snapshot Pipeline represents progress of R&D programs as of August 1, 2023 8 programs advanced or are new 9 programs discontinued since last update Included are 59 NMEs, 31 additional indications Discovery Projects With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements which Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer. With a vie w to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer. zpyi ztcw lpltrt lavvo wvwox qneks bzoewt abogv rvlg voyelr